Main characteristics of patients at APL diagnosis and treatments administered
| Patient no. . | Sex/age, y . | WBC (× 109/L) . | Platelets (× 109/L) . | PML/RARα Isoform . | Front-line therapy* . | Maintenance treatment . | APL relapse . | Salvage therapy for APL relapse . |
|---|---|---|---|---|---|---|---|---|
| 1 | F/16 | 1.4 | 185 | ND | GIMEMA 0389 | MTX, 6-MP | No | No |
| 2 | F/52 | 1.5 | 12 | BCR1 | AIDA | ATRA plus MTX, 6-MP | No | No |
| 3 | M/63 | 6.3 | 99 | BCR1 | AIDA | ATRA plus MTX, 6-MP | No | No |
| 4 | M/35 | 43.7 | 30 | ND | GIMEMA 0389 | MTX, 6-MP | First | ATRA + CHT† + AuSCT‡ |
| 5 | F/31 | 19.5 | 210 | BCR3 | AIDA | MTX, 6-MP | First | ATRA + CHT† + AuSCT‡ |
| Second | ATRA + CHT† |
| Patient no. . | Sex/age, y . | WBC (× 109/L) . | Platelets (× 109/L) . | PML/RARα Isoform . | Front-line therapy* . | Maintenance treatment . | APL relapse . | Salvage therapy for APL relapse . |
|---|---|---|---|---|---|---|---|---|
| 1 | F/16 | 1.4 | 185 | ND | GIMEMA 0389 | MTX, 6-MP | No | No |
| 2 | F/52 | 1.5 | 12 | BCR1 | AIDA | ATRA plus MTX, 6-MP | No | No |
| 3 | M/63 | 6.3 | 99 | BCR1 | AIDA | ATRA plus MTX, 6-MP | No | No |
| 4 | M/35 | 43.7 | 30 | ND | GIMEMA 0389 | MTX, 6-MP | First | ATRA + CHT† + AuSCT‡ |
| 5 | F/31 | 19.5 | 210 | BCR3 | AIDA | MTX, 6-MP | First | ATRA + CHT† + AuSCT‡ |
| Second | ATRA + CHT† |
ND indicates not determined.
As determined by RT-PCR. See “Patients, materials, and methods” for front-line treatment protocols GIMEMA 0389 and AIDA.
Chemotherapy for APL relapse included mitoxantrone and cytarabine.
Southern blot analysis was used in these 2 patients to identify RARα and PML gene rearrangement.